RT Journal Article SR Electronic T1 Estimation of fatality rate in Africa through the behavior of COVID-19 in Italy relevance to age profiles JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.21.20129049 DO 10.1101/2020.06.21.20129049 A1 Lambert Nzungize A1 Diane Umuhoza A1 Yongdong Dai A1 Stech A E. Nzaou A1 Mohammed Asaad A1 M. A. Abokadoum A1 Ulrich Aymard Ekomi Moure A1 Jianping Xie YR 2020 UL http://medrxiv.org/content/early/2020/06/22/2020.06.21.20129049.abstract AB The emergence and pandemic of COVID-19 has rapidly become a global concern. In Italy, on 27 March 2020, there were 8165 deaths and 80539 confirmed cases of COVID-19. Demographic situations, like age profiles is reported to be the cause of high case fatality rate (CFR) in Italy. In Africa, the COVID-19 pandemic has not yet grasped epic proportion, but the estimation of CFR is still needed. We compared the CFR observed in Italy with the age profiles in 46 Africa countries and 2 territories which are already confirmed COVID-19 case. The estimation of the CFR in Africa ranges between (1.0%-5.4%) while in Italy is 10.1%. The five highest CFR countries and territories in Africa are Reunion (5.4%), Mauritius (5.1%), Tunisia (3.9%), Seychelles (3.8%) and Morocco (3.3%). The last three countries with low CFR are Uganda (1.0%), Zambia (1.1%) and Angola (1.1%). The observed difference is related to the age profiles.Competing Interest StatementThe authors declare no competing interests.Funding StatementNo source of fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study does not require IRB/oversight approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo supplementary data